Castellví, Ivan http://orcid.org/0000-0002-5410-5807
,
Eguiluz, Saioa
Escudero-Contreras, Alejandro
Ríos, Juan José
Calvo-Alén, Jaime
Callejas-Rubio, José Luis
De la Puente, Carlos
Simeón, Carmen Pilar
Narváez, Francisco Javier
Espinosa, Gerard
Carreira, Patricia E.
Rubio-Rivas, Manuel
Alegre, Juan José
Guillén-Del-Castillo, Alfredo
Román-Ivorra, Jose Andrés
Fonollosa, Vicent
Funding for this research was provided by:
Actelion Pharmaceuticals
Article History
Received: 8 July 2019
Accepted: 24 August 2019
First Online: 14 September 2019
Compliance with ethical standards
:
: IC have received speaker fees from Actelion, Roche, BMS and Pfizer. JJR and JJA have received educational grants from Actelion outside the submitted work. JJA has also received speaker fees from Actelion. SE has received a grant from Actelion for the work under consideration, and personal fees from Actelion and an educational grant from GlaxoSmithKline outside the submitted work. JAR has been board member for Roche, Actelion, Lilly, Gebro and MSD, and has received speaker fees from Roche, Abbvie, Lilly, BMS, UCB, Novartis, Pfizer, Celgene, FER and SVR, and travel grants from Janssen, Pfizer and Gebro. AE-C, JC-A, JLCR, CdlP, CPS, FJN, GE, PEC, MR-R, AGdC, and VF declare that they have no conflict of interest.
: All procedures performed were in accordance with the ethical standards of the national research committees of the participant institutions and with the 1964 Helsinki declaration and its later amendments.
: Informed consent was obtained from all individual participants included in the study.